Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 9,172,293 |
|
|||||
| News | - | ||||||
| Day High | 0.0664 | Low High |
|||||
| Day Low | 0.0612 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Avalo Therapeutics Inc | AVTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.0039 | -5.99% | 0.0612 | 10:36:25 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0664 | 0.0612 | 0.0664 | 0.0651 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,573 | 9,172,293 | US$ 0.0647412 | US$ 593,825 | - | 0.0612 - 6.0865 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 10:36:32 | 2 | US$ 0.0616 | USD |
Avalo Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 563.68M | 192.38M | - | 18.05M | -41.66M | -0.22 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Avalo Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/16/2023 | 06:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/09/2023 | 06:21 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/09/2023 | 06:04 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/09/2023 | 06:00 | GlobeNewswire Inc. | Avalo Reports Third Quarter 2023 Financial Results and.. |
| 10/31/2023 | 06:21 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/31/2023 | 06:00 | GlobeNewswire Inc. | Avalo Completes Divestiture of AVTX-800 Series |
| 10/19/2023 | 15:15 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders |
| 10/19/2023 | 15:06 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 10/19/2023 | 15:01 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 10/17/2023 | 15:02 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/05/2023 | 15:02 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
| 9/26/2023 | 06:04 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0909 | 0.0945 | 0.0612 | 0.075066 | 18,630,464 | -0.0297 | -32.67% |
| 1 Month | 0.1039 | 0.12 | 0.0612 | 0.0921198 | 18,887,497 | -0.0427 | -41.1% |
| 3 Months | 0.0915 | 0.296 | 0.0612 | 0.1468696 | 79,801,587 | -0.0303 | -33.11% |
| 6 Months | 2.88 | 4.71 | 0.0612 | 0.1506796 | 40,403,706 | -2.82 | -97.88% |
| 1 Year | 5.62 | 6.0865 | 0.0612 | 0.1531005 | 20,218,196 | -5.56 | -98.91% |
| 3 Years | 2.87 | 7.13 | 0.0612 | 0.1801409 | 9,092,898 | -2.81 | -97.87% |
| 5 Years | 2.87 | 7.13 | 0.0612 | 0.1801409 | 9,092,898 | -2.81 | -97.87% |
Avalo Therapeutics Description
| Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. |
